News

Apeptico completes €3.4m financing round
Enlarge image

BusinessAustriaGermanySwitzerland

Apeptico completes €3.4m financing round

18.05.2012 - Austrian peptide drug developer Apeptico F&E GmbH has secured €3.4m financing.

Vienna – The Apeptico equity financing combined existing and new private and institutional investors, as well as a research grant from the Austrian Research Promotion Agency (FFG). Institutional and private investors contributed a total of €2m to the Series C financing – among them BioScience Venture Group, V+ GmbH & Co Fonds 2 KG, V+ GmbH & Co Fonds 3 KG, and business angels from Germany, Switzerland and the USA. At the end of 2011, Apeptico had already secured a research grant of €1.4m from the Austrian Research Promotion Agency FFG. 

Dr. Bernhard Fischer, CEO of Apeptico, commented: “This round C financing enables us to continue the clinical development of our lead peptide AP301. AP301 will be assessed in a “proof of concept” study in intensive care patients to investigate the clinical effect of repetitive orally inhaled doses of AP301 on alveolar liquid clearance in acute lung injury.“ 

AP301 is a patented (AT_507_953), water soluble, synthetic cyclic peptide in clinical development that mimics the lectin-like domain of the human tumour necrosis factor alpha (TNFalpha). It can be administered into the lung by instillation or by oral inhalation. AP301 was originally designed for the treatment of acute lung injury and acute respiratory distress syndrome. Additional research demonstrated that AP301 has additional significant potential in related clinical indications, such as prevention and treatment of pulmonary permeability oedema, prevention of progression of acute hypoxemic respiratory failure due to bacterial/viral pneumonia and prevention of ischemia reperfusion injury. 

http://www.european-biotechnology-news.com/news/news/2012-02/apeptico-completes-eur34m-financing-round.html

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

FinancingGermanyNetherlandsEU

12.04.2016 German-Dutch life science investment specialist Forbion Capital Partners has raised more than €180m for its venture capital fund Forbion Capital Fund III. Once more the money will primarily go to European start-ups.

Event ReviewGermanyEU

08.04.2016 Do you win by being innovative?, was the question asked at this year’s DIA Euromeeting in Hamburg. In a relaxed and cooperative atmosphere, regulators, physicians and patients had ample opportunity to interact with the healthcare industry.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • FORMYCON (D)24.56 EUR5.59%

FLOP

  • SERODUS (N)1.46 NOK-14.12%
  • PHOTOCURE (N)39.50 NOK-7.49%
  • BIONOR PHARMA (N)0.79 NOK-7.06%

TOP

  • AB SCIENCE (F)18.84 EUR71.3%
  • SYNAIRGEN (UK)35.75 GBP45.9%
  • BIOFRONTERA (D)3.17 EUR36.1%

FLOP

  • SERODUS (N)1.46 NOK-28.8%
  • THERAMETRICS (CH)0.03 CHF-25.0%
  • OREXO (S)50.00 SEK-19.4%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)31.20 SEK2022.4%
  • NICOX (F)8.55 EUR352.4%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.10 SEK-88.0%
  • BB BIOTECH (D)46.44 EUR-82.3%
  • BIOTEST (D)16.69 EUR-76.5%

No liability assumed, Date: 01.05.2016